<DOC>
	<DOCNO>NCT02481661</DOCNO>
	<brief_summary>Anatomic segmentectomy may less invasive type surgery lobectomy cT1aN0M0 peripheral NSCLC may retain pulmonary function . It yet know whether anatomic segmentectomy non-inferior lobectomy treat stage IA non-small cell lung cancer . The aim study investigate whether outcome anatomic segmentectomy similar lobectomy peripheral stage IA ( ≤ 2cm ) non-small cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>Comparison Lobectomy Segmentectomy cT1aN0M0 Peripheral NSCLC</brief_title>
	<detailed_description>Objective : To compare outcome ( include 5 year relapse free survival rate , 5 year overall survival rate , retain pulmonary function rate loco-regional systemic recurrence ) patient peripheral stage IA ( ≤ 2 cm ) non-small cell lung cancer undergo anatomic segmentectomy v lobectomy . And evaluate whether anatomic segmentectomy optimal type surgery patient peripheral stage IA ( ≤ 2cm ) non-small cell lung cancer ( NSCLC ) . Outline : This multicenter , prospective , randomized open phase III study anatomic segmentectomy vs lobectomy patient peripheral stage IA ( ≤ 2cm ) non-small cell lung cancer ( NSCLC ) . According completely random block design , patient randomize 1 2 treatment arm . - Arm I : Patients undergo anatomic segmentectomy minimal incision thoracotomy thoracoscopy/VATS . - Arm II : Patients undergo lobectomy minimal incision thoracotomy thoracoscopy/VATS . Patients follow every 3 month first year every 6 month subsequent 2 year annually 5 year postoperatively .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>1 . Age 1870y 2 . Preoperative criterion : ⅰ ) Center tumor locate out third lung field , maximal diameter ≤ 2 cm ( include coronal , traverse sagittal view ) confirm 1mm thin layer contrastenhanced CT scan . ⅱ ) hilar mediastinal lymph node metastasis verify mediastinoscope/EBUS . 3 . Intraoperative criterion : ⅰ ) Adenocarcinama squamous cell carcinoma lung confirm frozen section . ⅱ ) Lobectomy , single segmentectomy combine segmentectomy feasible . ⅲ ) Confirmation N0 status frozen section examination nodal level 10 13 segmentectomy , 10 lobectomy . 4 . ECOG performance status 02 . 5 . No malignancy within past 3 year ( except well prognostic malignancy basal cell carcinoma skin , superficial bladder cancer , carcinoma situ cervix ) . 6 . No prior ipsilateral thoracotomy ( prior diagnostic thoracoscopy allow ) . 7 . No prior chemotherapy radiation therapy . 8 . Lobectomy tolerate . 9 . Sufficient organ function . 10 . Written informed consent . 1 . Active bacterial fungous infection . 2 . Simultaneous metachronous ( within past 5 year ) multiple cancer . 3 . Interstitial pneumonitis , pulmonary fibrosis , severe pulmonary emphysema , tolerate lobectomy . 4 . Psychosis . 5 . Uncontrollable diabetes mellitus . 6 . History severe heart disease . 7 . The maximal diameter GGO≤5mm . 8 . N1 , N2 , M1a confirm postoperatively . 9 . Postoperative adjuvant therapy ( chemotherapy , radiotherapy target therapy ) . 10 . Other type lung cancer small cell lung cancer , large cell lung cancer , etc . 11 . Confirmation benign disease postoperative pathologic examination . 12 . Lesion locate middle lobe .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>